Literature DB >> 9559674

Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs.

K Yuasa1, Y Miyagoe, K Yamamoto, Y Nabeshima, G Dickson, S Takeda.   

Abstract

A series of truncated dystrophin cDNAs (3.1-4.2 kbp) containing only three, three, two or one rod repeats with hinge 1 and 4 (named deltaDysAX2, AX11, AH3, M3, respectively) or no rod repeat retaining either hinge 1 or 4 (named deltaDysH1, H4, respectively) were constructed. These cDNAs were introduced into skeletal muscle of adult mdx mice using the adenovirus vector with a strong CAG promoter. deltaDysAX2, AX11, AH3 and deltaDysM3 expressed themselves successfully and recovered dystrophin-associated proteins effectively. Especially 3.7 kbp cDNA for deltaDysM3 offers the possibility of an approach utilizing newly developed virus vectors, such as an adeno-associated virus vector, toward gene therapy of Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559674     DOI: 10.1016/s0014-5793(98)00251-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  A New Kid on the Playground of CRISPR DMD Therapy.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

Review 3.  Nanotherapy for Duchenne muscular dystrophy.

Authors:  Michael E Nance; Chady H Hakim; N Nora Yang; Dongsheng Duan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-11

Review 4.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

5.  The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins.

Authors:  Glen B Banks; Luke M Judge; James M Allen; Jeffrey S Chamberlain
Journal:  PLoS Genet       Date:  2010-05-20       Impact factor: 5.917

Review 6.  Progress toward Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2017-04-15       Impact factor: 12.910

Review 7.  Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era.

Authors:  Eijiro Ozawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

8.  Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing.

Authors:  J Y Lee; Z Qu-Petersen; B Cao; S Kimura; R Jankowski; J Cummins; A Usas; C Gates; P Robbins; A Wernig; J Huard
Journal:  J Cell Biol       Date:  2000-09-04       Impact factor: 10.539

9.  Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.

Authors:  Peggy P Ho; Lauren J Lahey; Foteini Mourkioti; Peggy E Kraft; Antonio Filareto; Moritz Brandt; Klas E G Magnusson; Eric E Finn; Jeffrey S Chamberlain; William H Robinson; Helen M Blau; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 12.779

10.  Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy.

Authors:  Takashi Okada; Shin'ichi Takeda
Journal:  Pharmaceuticals (Basel)       Date:  2013-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.